Kobayashi A, Yamaguchi M
Dept. of Surgery, Shadan-tohkokkai Chofu Hospital.
Gan To Kagaku Ryoho. 2001 Jul;28(7):1003-7.
Recently, as society ages there have become more elderly gastric cancer patients with/without several complications(cerebrovascular diseases, cardiac diseases, atherosclerosis, DM, etc.), that were non-resected and require highly effective chemotherapy and good QOL. We report two elderly gastric cancer patients responding to chronomodulation chemotherapy (tegafur + cisplatin + Isovorin) based on circadian rhythms plus a new antitumor drug, S-1. The treatment protocol was tegafur 800 mg/body, days 1-7 (continuing 16 h, intravenously with 500 mg/body from 16 to 0 h, 300 mg/body from 0-8 h, for non-uniform administration), cisplatin 10 mg/body, days 1-5, (16 h), Isovorin 25 mg/body, days 1-5, (16 h, oneshot infusion, for 4 courses followed by a week rest. Next was S-1 120 mg/body x 2 times orally for 28 days, followed by 2 weeks rest, the administered for another 28 days. The first patient was 74 years of age, with advanced type 3 plus early type IIc gastric cancers with liver metastasis (H1). After chemotherapy the liver metastasis disappeared, there was a 70% reduction in the advanced cancer and the early cancer disappeared. The second patient was 84 years of age, with advanced type 3 gastric cancer invading the esophagus. After chemotherapy, the primary lesion was reduced 80% and the esophageal invasion mass shrunk. The only adverse effect was grade 2 pancytopenia. In conclusion this regimen resulted in good intrachemotherapeutic QOL and highly effective performance in elderly advanced gastric cancer patient.
近年来,随着社会老龄化,出现了越来越多伴有或不伴有多种并发症(脑血管疾病、心脏病、动脉粥样硬化、糖尿病等)的老年胃癌患者,这些患者无法接受手术切除,需要高效化疗且生活质量良好。我们报告了两名老年胃癌患者,他们对基于昼夜节律的时辰调制化疗(替加氟+顺铂+亚叶酸钙)以及一种新型抗肿瘤药物S-1有反应。治疗方案为替加氟800mg/人,第1 - 7天(持续16小时,从16点至0点静脉注射500mg/人,从0点至8点静脉注射300mg/人,不均匀给药),顺铂10mg/人,第1 - 5天(16小时),亚叶酸钙25mg/人,第1 - 5天(16小时,单次输注,共4个疗程,之后休息一周。接下来是S-1 120mg/人,口服2次,共28天,之后休息2周,再给药28天。第一位患者74岁,患有进展期3型加早期IIc型胃癌并伴有肝转移(H1)。化疗后肝转移消失,进展期癌症缩小70%,早期癌症消失。第二位患者84岁,患有侵犯食管的进展期3型胃癌。化疗后,原发灶缩小80%,食管侵犯肿块缩小。唯一的不良反应是2级全血细胞减少。总之,该方案在老年晚期胃癌患者中化疗期间生活质量良好且疗效显著。